Liminatus Pharma Charts Dual-Front Attack on Cancer with IBA101

Key Takeaways:

• Liminatus Pharma’s IBA101 advances toward human trials in the U.S. and Korea.
• IBA101 is designed to avoid anemia and thrombocytopenia seen in earlier CD47 inhibitors.
• The drug employs a dual-action mechanism enhancing the immune response against tumors.
• Preclinical studies show no significant reductions in hemoglobin or platelet counts.
• A collaboration with Dr. Se-Hoon Lee and Samsung Medical Center strengthens clinical efforts.

Overcoming Past Hurdles in Cancer Treatment

Interest in CD47 blockade as a cancer treatment has been intense but challenging. Previous efforts by companies like Gilead and Pfizer were halted due to severe anemia and thrombocytopenia caused by off-target binding to red blood cells (RBCs) and platelets. These side effects underscored the need for a safer approach to targeting CD47, a protein that tumors exploit to evade the immune system’s “don’t-eat-me” signal.

IBA101’s Innovative Design

Liminatus Pharma aims to overcome these hurdles with IBA101, a novel CD47 checkpoint inhibitor engineered to eliminate the anemia and thrombocytopenia that limited earlier candidates. By sparing RBCs and platelets through targeted epitope selection and Fc engineering, IBA101 selectively binds CD47 epitopes on tumor and immune cells. “Additional glycosylation on RBC and platelet CD47 proteins prevents IBA101 engagement,” the company explained, minimizing off-target interactions and reducing the risk of cytopenias.

Promising Preclinical Results

Pivotal Good Laboratory Practice (GLP) toxicology and pharmacology studies conducted in non-human primates at Charles River Laboratories showed that IBA101 did not induce clinically meaningful reductions in hemoglobin or platelet counts. These findings suggest a markedly improved safety profile compared to previous CD47 inhibitors. “IBA101 enables higher dosing levels—potentially unlocking more robust anti-tumor responses without compromising patient safety,” Liminatus stated.

A Dual-Front Attack on Cancer

IBA101 employs a two-pronged approach to enhance the body’s immune response against cancer. First, it blocks CD47 on tumor cells, reactivating macrophage-mediated clearance. Second, it remodels the tumor microenvironment by enhancing macrophage turnover and antigen presentation, priming T cells for more potent cytotoxicity. In preclinical combination studies, pairing IBA101 with PD-1/PD-L1 inhibitors resulted in significant increases in complete response rates versus monotherapy, bolstering expectations for superior clinical efficacy.

Strategic Collaboration Enhances Clinical Efforts

To advance IBA101 into human trials, Liminatus has partnered with Dr. Se-Hoon Lee, a leading lung cancer specialist at Samsung Medical Center in Seoul, South Korea. This collaboration secures access to advanced non-small-cell lung cancer (NSCLC) patients and cutting-edge translational laboratories. The Phase 1 protocol will integrate serial tumor biopsies, immune-cell phenotyping, and multimodal omics analyses. Featuring a 3 + 3 dose-escalation design followed by expansion cohorts and adaptive combination arms with approved PD-1/PD-L1 agents, the trial aims to elucidate the specific conditions under which IBA101 delivers superior anti-tumor efficacy.

Looking Ahead: From Lab to Clinic

With Investigational New Drug (IND) applications to be submitted to the U.S. Food and Drug Administration (FDA) and Korea’s Ministry of Food and Drug Safety (MFDS) in the second half of 2026, Liminatus anticipates site activations and patient screening to begin in early 2027. The company’s meticulous preparation, including completing pivotal GLP studies and downstream process development for clinical-grade production, positions IBA101 as a promising candidate in the immuno-oncology landscape.

Conclusion

Liminatus Pharma’s IBA101 represents a significant advancement in cancer immunotherapy, potentially overcoming the limitations that plagued earlier CD47 inhibitors. By targeting tumors while sparing healthy cells, IBA101 offers renewed hope for effective and safe cancer treatments. As the drug moves toward clinical trials, the medical community watches with anticipation for its potential to redefine cancer care.